Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/56367

Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients
Freitas, P.; Carvalho, D.; Souto, S.; Santos, A. C.; Xerinda, S.; Marques, R.; Martínez Chamorro, Esteban José; Sarmento, A.; Medina, J. L.
Universitat de Barcelona
BACKGROUND: In HIV-infected patients, combination antiretroviral therapy (cART) is associated with clinical lipodystrophy (CL) and metabolic abnormalities (MA). This study aimed to evaluate the prevalence of the metabolic syndrome (MS) and its components, and to determine whether patients with or without CL had a different prevalence of MA. METHODS: We evaluated 345 HIV-infected patients on cART using two different MS definitions (NCEP-ATPIII-2005 and IDF-2005) and the Framingham risk score. RESULTS: CL was present in 58.7% of the patients. The prevalence of the MS was 52.2% (ATPIII) and 43.2% (IDF), and it was not significantly different between patients with (W) or without (WT) CL, regardless of the definition used (ATPIII WCL 52.9% vs WT CL 51.1%; p = 0.738; IDF WCL 41.3% vs WTCL 46.0%; p = 0.379). Moderate concordance was observed between the 2 definitions (kappa = 0.484; p < 0.001) and after gender stratification there was good concordance in women (kappa = 0.759; p < 0.001). Patients with CL had lower waist circumference and HDL-C and higher triglycerides levels. In women, CL was significantly associated with MS, hypertriglyceridemia and low HDL cholesterol independently of age, cART and BMI. Patients with CL had a significantly higher risk of coronary heart disease at 10 years, measured by the Framingham risk score, than patients without CL. Those with CL and with MS had higher frequencies of moderate and high risk categories than those without MS. CONCLUSIONS: The prevalence of the MS was high in these HIV-infected patients with an age average of 40 years and this finding could explain why HIV patients have an increased risk for cardiovascular disease (CVD).
Síndrome de lipodistròfia associada a VIH
Síndrome metabòlica
Malalties cardiovasculars
Infeccions per VIH
HIV-associated lipodystrophy syndrome
Metabolic syndrome
Cardiovascular diseases
HIV infections
cc-by (c) Freitas, P. et al., 2011
http://creativecommons.org/licenses/by/3.0/es
Artículo
info:eu-repo/semantics/publishedVersion
BioMed Central
         

Mostrar el registro completo del ítem

Documentos relacionados

Otros documentos del mismo autor/a

Freitas, P.; Carvalho, D.; Santos, A. C.; Mesquita, J.; Matos, M. J.; Madureira, A. J.; Martínez Chamorro, Esteban José; Sarmento, A.; Medina, JL.
Cereijo Téllez, Rubén; Gallego Escuredo, José Miguel; Moure Ortega, Ricardo; Villarroya i Terrade, Joan; Domingo i Pedrol, Joan Carles; Fontdevila Font, Joan; Martínez Chamorro, Esteban José; Gutiérrez, Maria del Mar; Gracia Mateo, María; Giralt i Oms, Marta; Domingo, Pere; Villarroya i Gombau, Francesc
Cereijo Téllez, Rubén; Gallego Escuredo, José Miguel; Moure Ortega, Ricardo; Villarroya i Terrade, Joan; Domingo i Pedrol, Joan Carles; Fontdevila Font, Joan; Martínez Chamorro, Esteban José; Gutiérrez, Maria del Mar; Gracia Mateo, María; Giralt i Oms, Marta; Domingo, Pere; Villarroya i Gombau, Francesc
Egana-Gorrono, L.; Martínez Chamorro, Esteban José; Escribà, T.; Calvo, M.; Gatell, José M.; Arnedo, M.